Interpretation 341
Tier 1|
|
|
Variants
Primary Sites
Interpretation
PTCH1 loss of function mutations are associated with Vismodegib sensitivity in basal cell carcinoma. However, the clinical significance in other tumor types is unknown.
Citations
- Sandhiya S, et al. The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother 2013;4(1):4-7
- Yin VT, et al. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg 2013;29(2):87-92
- Von Hoff DD, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361(12):1164-72
Last updated: 2017-01-20 03:36:18 UTC